Novartis Ag

Atsuko Iwasaki

Keiichi Masuya

Takeru Ehara

Fumiaki Yokokawa

Werner Breitenstein

Claus Ehrhardt

Yuki Iwaki

Philipp Grosche

Nils Ostermann

Juergen Klaus Maibaum

Junichi Sakaki

Terance William Hart

Takanori Kanazawa

Osamu Irie

Kazuhide Konishi

Masaki Suzuki

Yuko Hitomi

Atsushi Toyao

Masashi Kishida

Allan Hallett

Hajime Hirao

3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification. 

Organic compounds

The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein

Compounds and compositions useful as cathepsin S inhibitors

Growing community of inventors

Tsukuba, Japan

Atsuko Iwasaki